A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jun Zhu
• Treatments: Aprepitant; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Fosaprepitant; Tropisetron

Criteria

Inclusion Criteria:

• Men and women >/= 18 years, <65 years

• Patients with lymphoma receiving autologous hematopoietic stem cell transplantation for the first time

• ECOG 0-2

• TBIL,AST and ALT < 2.5-fold upper normal range

• Female and male subjects of childbearing potential must agree to use a medically accepted method of adequate contraception.

• Signed informed consent

Exclusion Criteria:

• Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma

• Women who are pregnant or breast feeding.

• Serious or uncontroled infection

• Serious complications

• Severe renal or hepatic disease

• Severe mental or nervous system diseases